Coadministration has not been studied but is expected to decrease dolutegravir exposure due to induction of UGT1A1 and CYP3A by eslicarbazepine. Interaction studies with dolutegravir and rifampicin (a strong inducer) showed that the effect of induction on dolutegravir concentrations can be overcome by administering an additional 50 mg dose of dolutegravir. Although no dosing recommendations are provided for eslicarbazepine, the European and US product labels for dolutegravir recommend dolutegravir 50 mg twice daily in presence of carbamazepine (another anticonvulsant with inducing properties) in treatment-naive or treatment experienced, INSTI-naive patients. This dose adjustment should be maintained for approximately 2 weeks after stopping eslicarbazepine as the inducing effect may persist after discontinuation of a strong inducer. Alternatives to eslicarbazepine should be used where possible for INSTI resistant patients.